ReviewSeminars in oncology2012
The current state of targeted therapy in melanoma: this time it's personal.
Review in Seminars in oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Single-cell transcriptomics identifies FOSL1-regulated IGFBP3+ melanoma subtype as a neuro-immunoregulatory signaling hub facilitating tumor progression.Frontiers in immunology · 2025Article
- Immunotherapy for the treatment of advanced nasopharyngeal carcinoma: a promising new era.Journal of cancer research and clinical oncology · 2023Review
- Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression.Scientific reports · 2018Article
- Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Review
- Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines.Cancer biology & therapy · 2016Article
- Article
- Primary gastric melanoma: case report of a rare malignancy.Rare tumors · 2015Article
- Integration of Mitochondrial Targeting for Molecular Cancer Therapeutics.International journal of cell biology · 2015Review
- Targeting multiple key signaling pathways in melanoma using leelamine.Molecular cancer therapeutics · 2014Article
- Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.Molecular cancer therapeutics · 2013Article
- Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth.Cancer prevention research (Philadelphia, Pa.) · 2013Article
- Advances in the development of cancer immunotherapies.Trends in immunology · 2013Review
- The molecular genetics of eyelid tumors: recent advances and future directions.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Treatment of metastatic melanoma has long been a challenge. Over the past 8 years significant advances have been made in understanding the genetic changes that drive melanoma development and progression. These studies have shown melanoma to be a heterogeneous group of tumors, driven by a diverse array of oncogenic mutations. There is now good evidence that activating mutations in the serine/threonine kinase BRAF and the receptor tyrosine kinase KIT constitute good therapeutic targets for restricted subgroups of melanoma. In this article, we discuss the genetics and etiology of cutaneous and noncutaneous melanoma and review some of the latest preclinical and clinical data on the new targeted therapy agents that are beginning to make an impact on the lives of melanoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.